Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 264

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 11
Chunk 264
---
 information provided to us, that each of the stockholders listed below has sole voting and investment power with
respect to the shares beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable.

    Name of Beneficial Owner 
    Number of Shares Beneficially Owned  
    Percentage of Shares Beneficially Owned 
  
    Persons or entities holding 5% or more our outstanding common stock 

    Glen R. Anderson 
     1,190,400(1) 
     8.2%
  
    Matthew Joseph Nachtrab Revocable Trust dtd 12/15/2014 
     2,142,462(2) 
     13.8%
  
    Yehuda Shimoni 
     1,644,300(3) 
     10.8%
  
    Thomas Mollick 
     2,438,598(4) 
     15.7%

    Named executive officers and directors 

    Michael J. Newman, Ph.D. 
     1,752,164(5) 
     11.8%
  
    Jeffrey A. Meckler 
     1,035,636(6) 
     6.8%
  
    Roger Waltzman, M.D. 
     83,750(7) 
      * 
  
    Walt A. Linscott, Esq. 
     325,750(8) 
     2.2%
  
    Hila Karah 
     41,281(9) 
     * 
  
    Anthony J. Maddaluna 
     41,670(10) 
     * 
  
    William B. Hayes 
     41,000(11) 
     * 
  
    Dr. Roger J. Pomerantz 
     153,000(12) 
     1.1%
  
    Mark Gilbert, M.D. 
     46,250(13) 
     * 
  
    Robert E. Martell, M.D., Ph.D. 
     20,000(14) 
     * 
  
    All executive officers and directors as a group (11 persons) 
     3,690,334(15) 
     22.3%

    *
    Less than one
    percent.

91

    (1)
    Based
solely upon a Schedule 13G/A filed with the SEC on